Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Depreciation & Amortization (CF): 2010-2024

Historic Depreciation & Amortization (CF) for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $4.3 million.

  • OptimizeRx's Depreciation & Amortization (CF) fell 136.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 235.74%. This contributed to the annual value of $4.3 million for FY2024, which is 8022.48% up from last year.
  • As of FY2024, OptimizeRx's Depreciation & Amortization (CF) stood at $4.3 million, which was up 8022.48% from $2.4 million recorded in FY2023.
  • OptimizeRx's Depreciation & Amortization (CF)'s 5-year high stood at $4.3 million during FY2024, with a 5-year trough of $95202.0 in FY2020.
  • Over the past 5 years, OptimizeRx's median Depreciation & Amortization (CF) value was $2.0 million (recorded in 2022), while the average stood at $2.2 million.
  • In the last 5 years, OptimizeRx's Depreciation & Amortization (CF) tumbled by 9257.85% in 2020 and then surged by 196437.36% in 2021.
  • OptimizeRx's Depreciation & Amortization (CF) (Annual) stood at $95202.0 in 2020, then skyrocketed by 1964.37% to $2.0 million in 2021, then rose by 2.89% to $2.0 million in 2022, then increased by 18.79% to $2.4 million in 2023, then surged by 80.22% to $4.3 million in 2024.
  • Its Depreciation & Amortization (CF) was $4.3 million in FY2024, compared to $2.4 million in FY2023 and $2.0 million in FY2022.